Forum's Lead Drug Program Fails In Phase III Schizophrenia Trials
This article was originally published in Scrip
Forum Pharmaceuticals' lead compound encenicline has failed to meet the endpoints in two Phase III trials for the treatment of cognitive impairment in schizophrenia patients. .
Register for our free email digests: